NRX Long Term Debt To Capitalization from 2010 to 2025

NRXP Stock  USD 2.27  0.02  0.87%   
NRX Pharmaceuticals Long Term Debt To Capitalization yearly trend continues to be relatively stable with very little volatility. Long Term Debt To Capitalization is likely to grow to 0.26 this year. During the period from 2010 to 2025, NRX Pharmaceuticals Long Term Debt To Capitalization destribution of quarterly values had r-value of  0.80 from its regression line and median of  0.01. View All Fundamentals
 
Long Term Debt To Capitalization  
First Reported
2010-12-31
Previous Quarter
0.25
Current Value
0.26
Quarterly Volatility
0.12307037
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NRX Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NRX Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 372.8 K, Interest Expense of 131.1 K or Selling General Administrative of 20.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NRX financial statements analysis is a perfect complement when working with NRX Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of NRX Pharmaceuticals Correlation against competitors.
To learn how to invest in NRX Stock, please use our How to Invest in NRX Pharmaceuticals guide.

Latest NRX Pharmaceuticals' Long Term Debt To Capitalization Growth Pattern

Below is the plot of the Long Term Debt To Capitalization of NRX Pharmaceuticals over the last few years. It is NRX Pharmaceuticals' Long Term Debt To Capitalization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NRX Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Long Term Debt To Capitalization10 Years Trend
Slightly volatile
   Long Term Debt To Capitalization   
       Timeline  

NRX Long Term Debt To Capitalization Regression Statistics

Arithmetic Mean0.09
Coefficient Of Variation133.47
Mean Deviation0.11
Median0.01
Standard Deviation0.12
Sample Variance0.02
Range0.2885
R-Value0.80
Mean Square Error0.01
R-Squared0.64
Significance0.0002
Slope0.02
Total Sum of Squares0.23

NRX Long Term Debt To Capitalization History

2025 0.26
2024 0.25
2021 0.28
2020 -0.0127
2019 0.0621

About NRX Pharmaceuticals Financial Statements

NRX Pharmaceuticals shareholders use historical fundamental indicators, such as Long Term Debt To Capitalization, to determine how well the company is positioned to perform in the future. Although NRX Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in NRX Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on NRX Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Long Term Debt To Capitalization 0.25  0.26 

Additional Tools for NRX Stock Analysis

When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.